Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 35Breast Neoplasms 27Prostatic Neoplasms 22Stomach Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Neoplasms 10Lung Neoplasms 10Urinary Bladder Neoplasms 8Head and Neck Neoplasms 8Triple Negative Breast Neoplasms 7Neoplasm Metastasis 7Carcinoma, Squamous Cell 6Non-Muscle Invasive Bladder Neoplasms 5Nasopharyngeal Carcinoma 5Carcinoma, Transitional Cell 5Adenocarcinoma 5Oropharyngeal Neoplasms 4Sarcoma 3Prostatic Neoplasms, Castration-Resistant 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3HER2-positive Breast Cancer 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Vaccinia 2Recurrence 2Peritoneal Neoplasms 2Metastatic Castration-Resistant Prostate Cancer 2

Interventions

trastuzumab deruxtecan 1taxane 1sacituzumab govitecan 1liposomal doxorubicin 1eribulin 1Vinorelbine 1Paclitaxel 1Gemcitabine 1Epirubicin 1Docetaxel 1Cyclophosphamide 1Carboplatin 1Capecitabine 1Anthracyclines 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × HER2-negative Breast Cancer × Docetaxel × Clear all
NCT04576143 2021-08-12

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2/3 Recruiting
260 enrolled
Breast

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡